Medtronic PLC $MDT Shares Purchased by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC boosted its holdings in Medtronic PLC (NYSE:MDT) by 36.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,275 shares of the medical technology company’s stock after buying an additional 5,105 shares during the period. Smartleaf Asset Management LLC’s holdings in Medtronic were worth $1,811,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Twin Capital Management Inc. boosted its position in shares of Medtronic by 41.3% in the third quarter. Twin Capital Management Inc. now owns 35,306 shares of the medical technology company’s stock worth $3,363,000 after acquiring an additional 10,311 shares during the last quarter. RBA Wealth Management LLC raised its stake in Medtronic by 1.8% during the third quarter. RBA Wealth Management LLC now owns 54,330 shares of the medical technology company’s stock worth $5,174,000 after purchasing an additional 976 shares during the period. Murphy Pohlad Asset Management LLC boosted its holdings in shares of Medtronic by 0.5% in the 3rd quarter. Murphy Pohlad Asset Management LLC now owns 67,094 shares of the medical technology company’s stock valued at $6,390,000 after purchasing an additional 350 shares during the last quarter. Spinnaker Trust boosted its holdings in shares of Medtronic by 1.4% in the 3rd quarter. Spinnaker Trust now owns 22,278 shares of the medical technology company’s stock valued at $2,122,000 after purchasing an additional 310 shares during the last quarter. Finally, Coston McIsaac & Partners grew its stake in shares of Medtronic by 0.3% during the 3rd quarter. Coston McIsaac & Partners now owns 56,021 shares of the medical technology company’s stock valued at $5,334,000 after buying an additional 142 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 0.1%

Shares of NYSE:MDT opened at $102.89 on Monday. The company has a market capitalization of $131.91 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71. The company has a 50 day moving average of $99.40 and a two-hundred day moving average of $96.16. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the prior year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s payout ratio is 76.55%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Barclays lifted their target price on Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a report on Thursday, January 8th. Royal Bank Of Canada lifted their price objective on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Jefferies Financial Group restated a “hold” rating and issued a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.67.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).